- Home
- KRMD vs ABOS Comparison
KRMD vs ABOS Comparison
Compare KRMD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- ABOS
- Stock Information
- Founded
- KRMD 1980
- ABOS 1996
- Country
- KRMD United States
- ABOS United States
- Employees
- KRMD N/A
- ABOS N/A
- Industry
- KRMD Medical/Dental Instruments
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- ABOS Health Care
- Exchange
- KRMD Nasdaq
- ABOS Nasdaq
- Market Cap
- KRMD 145.4M
- ABOS 171.8M
- IPO Year
- KRMD N/A
- ABOS 2021
- Fundamental
- Price
- KRMD $3.17
- ABOS $2.40
- Analyst Decision
- KRMD Strong Buy
- ABOS Strong Buy
- Analyst Count
- KRMD 4
- ABOS 4
- Target Price
- KRMD $4.13
- ABOS $9.00
- AVG Volume (30 Days)
- KRMD 47.2K
- ABOS 207.8K
- Earning Date
- KRMD 11-13-2024
- ABOS 11-12-2024
- Dividend Yield
- KRMD N/A
- ABOS N/A
- EPS Growth
- KRMD N/A
- ABOS N/A
- EPS
- KRMD N/A
- ABOS N/A
- Revenue
- KRMD $31,993,796.00
- ABOS N/A
- Revenue This Year
- KRMD $15.46
- ABOS N/A
- Revenue Next Year
- KRMD $17.47
- ABOS N/A
- P/E Ratio
- KRMD N/A
- ABOS N/A
- Revenue Growth
- KRMD 11.57
- ABOS N/A
- 52 Week Low
- KRMD $1.98
- ABOS $2.08
- 52 Week High
- KRMD $3.40
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- KRMD 67.44
- ABOS 38.88
- Support Level
- KRMD $2.60
- ABOS $2.85
- Resistance Level
- KRMD $3.40
- ABOS $3.36
- Average True Range (ATR)
- KRMD 0.23
- ABOS 0.25
- MACD
- KRMD 0.05
- ABOS -0.08
- Stochastic Oscillator
- KRMD 73.86
- ABOS 3.03
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.